NJ-based Johnson & Johnson expects to release early data next week from Phase 3 clinical trials

New Brunswick-based Johnson & Johnson says it expects to release early data next week from the Phase 3 clinical trials of its vaccine.
The company came to an agreement over the summer with the federal government to deliver 100 million doses after getting approval for usage.
Johnson & Johnson's vaccine only requires one shot, unlike the currently available vaccines by Pfizer and Moderna.